Brachystemma calycinum D. Don Effectively Reduces the Locomotor Disability in Dogs with Naturally Occurring Osteoarthritis: A Randomized Placebo-Controlled TrialChondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science studyContribution of H3K4 methylation by SET-1A to interleukin-1-induced cyclooxygenase 2 and inducible nitric oxide synthase expression in human osteoarthritis chondrocytesEndothelin-1 in osteoarthritic chondrocytes triggers nitric oxide production and upregulates collagenase production.The Novartis-ILAR Rheumatology Prize 2001 Osteoarthritis: from molecule to manThe protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases.A reference case for economic evaluations in osteoarthritis: an expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)Cartilage-specific deletion of ephrin-B2 in mice results in early developmental defects and an osteoarthritis-like phenotype during aging in vivo.A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life settingDiacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEOOARSI Clinical Trials Recommendations: Hip imaging in clinical trials in osteoarthritisOARSI Clinical Trials Recommendations: Hand imaging in clinical trials in osteoarthritisNew emerging role of pitx1 transcription factor in osteoarthritis pathogenesisConcurrent validity of different functional and neuroproteomic pain assessment methods in the rat osteoarthritis monosodium iodoacetate (MIA) modelKinetic peak vertical force measurement in cats afflicted by coxarthritis: data management and acquisition protocols.First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort.Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR-27a in human osteoarthritic chondrocytes.Identification and differential expression of human collagenase-3 mRNA species derived from internal deletion, alternative splicing, and different polyadenylation and transcription initiation sites.Impact of disease treatments on the progression of knee osteoarthritis structural changes related to meniscal extrusion: Data from the OAI progression cohort.Long-Term Effects of Glucosamine and Chondroitin Sulfate on the Progression of Structural Changes in Knee Osteoarthritis: Six-Year Followup Data From the Osteoarthritis Initiative.Osteoarthritis: a metabolic disease induced by local abnormal leptin activity?Human hip joint cartilage: MRI quantitative thickness and volume measurements discriminating acetabulum and femoral head.Analgesic efficacy of tramadol in cats with naturally occurring osteoarthritis.Evoked temporal summation in cats to highlight central sensitization related to osteoarthritis-associated chronic pain: a preliminary studyThe association between subchondral bone cysts and tibial cartilage volume and risk of joint replacement in people with knee osteoarthritis: a longitudinal study.High mobility group box 1 potentiates the pro-inflammatory effects of interleukin-1β in osteoarthritic synoviocytes.Fully automated system for the quantification of human osteoarthritic knee joint effusion volume using magnetic resonance imaging.Clinical validity of outcome pain measures in naturally occurring canine osteoarthritisPPARgamma ligands as modulators of inflammatory and catabolic responses in arthritis. An overview.The role of cytokines in osteoarthritis pathophysiology.Bone marrow lesions predict site-specific cartilage defect development and volume loss: a prospective study in older adults.Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes.Most recent developments in strategies to reduce the progression of structural changes in osteoarthritis: today and tomorrow.Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRIThe presence of meniscal lesions is a strong predictor of neuropathic pain in symptomatic knee osteoarthritis: a cross-sectional pilot study.Low sirtuin 1 levels in human osteoarthritis subchondral osteoblasts lead to abnormal sclerostin expression which decreases Wnt/β-catenin activity.Meniscal extrusion promotes knee osteoarthritis structural progression: protective effect of strontium ranelate treatment in a phase III clinical trial.Meniscal tear and extrusion are strongly associated with progression of symptomatic knee osteoarthritis as assessed by quantitative magnetic resonance imaging.Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament modelCyclooxygenase-2 and prostaglandins in articular tissues.
P50
Q21285007-D131EB38-28AE-4EA8-A9A3-12BA9821DC9CQ22000858-85238391-A783-4A8B-86EF-3F80F9A5DCE2Q24300761-2934AD5F-910C-4237-A7AB-402F6767AAC4Q24804001-50B84AFE-459D-4CD5-A2E9-53AE57D50C45Q24805915-A0D9FB65-5BCE-4407-A169-23E984FB6BF3Q24812406-4073D558-7F17-4476-AC79-4FA2C81A96ECQ27015782-96B92AC4-2691-46CD-86CB-62E0F45AF86AQ27325791-E2BA1E9F-8B80-42B4-8E0C-605D289415EFQ28073729-D58BE3AB-89FC-48BA-B7F5-55748F030DB2Q28079515-B429840F-892D-44EE-8A12-49D4E2005488Q28082948-113997DC-FAAB-4F99-9E96-71D3C7B1FB03Q28083284-12BF6F09-1DCC-42FF-8D16-91B67A1EFA56Q28305076-DFADD6A0-EBBE-463C-9E3B-33458DBAB88CQ28829244-107A30C4-3559-479D-BC49-56B97B89F8C5Q30589519-007CF7B3-BD64-444D-894B-6A00EC500C04Q30714596-D44460F5-6D8F-4C30-B340-2B72DAFF6E67Q30931885-5A3B376D-87AF-4C77-A9A0-FA2B358102F3Q30949410-FEF33F0A-9F6D-4669-B1BF-99F9087ACC51Q30975609-F31DF87A-7CF7-4185-ACB1-C248786EC0FEQ31046250-A04F46EC-ACF5-4899-9A79-3801F2E83057Q33212755-B9C6F062-AF59-415E-86FC-10107F8EB83BQ33397893-0D39BB78-F0DC-4707-A054-9B43F8321CC5Q33558810-CC2E83CF-345F-4526-B67D-2F28347FFF4EQ33654756-72A7ED32-B45A-44D1-863E-60AB09EF05E7Q33923385-40138D25-20C1-4F50-B55B-08D5E926C150Q34153150-019DC182-0144-450C-A8AD-6B1DA54EE056Q34346229-D3AB993E-3B3E-42A3-AB59-59BD19668363Q34410470-96AB9107-1805-4D60-8B56-D1313C685BBEQ34515090-69A3BF92-6086-47B4-93A1-C385A2F2C8CFQ34524517-AEC86998-F799-4BA9-8016-ACFF000F708CQ34614059-56D36644-0773-4258-BE85-A351DC472083Q34896028-4F9E1059-40ED-40EE-BB6A-892579EBCB49Q34896866-8CED6A26-DCA7-43C4-A9E1-55C71D48FC5BQ34906145-7370D53D-CE99-4084-A767-79D52D0074B3Q34967738-8AE19E32-F3FC-48F1-9759-7F37C0391468Q35030853-CD42D4E9-BBD1-424F-BFF6-921826886C6CQ35531158-9AF7822F-56A7-41E3-B3EC-10FBA4FAF689Q35555395-F2AFDBAA-E2F1-488A-ACE1-4AB853E0C9E6Q35557938-2F4C2B29-7260-416C-8233-09388E1569EFQ35606373-03229A4F-829E-4AD8-AC15-A7C5E2AD0A7B
P50
description
Canadees farmacologe
@nl
Canadian pharmacologist
@en
Canadian pharmacologist
@en-ca
Canadian pharmacologist
@en-gb
farmacóloga canadiense
@es
kanadische Medizinerin
@de
عالمة صيدلية كندية
@ar
name
Johanne Martel-Pelletier
@ast
Johanne Martel-Pelletier
@ca
Johanne Martel-Pelletier
@de
Johanne Martel-Pelletier
@en
Johanne Martel-Pelletier
@es
Johanne Martel-Pelletier
@fr
Johanne Martel-Pelletier
@ga
Johanne Martel-Pelletier
@nl
Johanne Martel-Pelletier
@sl
Johanne Martel-Pelletier
@sq
type
label
Johanne Martel-Pelletier
@ast
Johanne Martel-Pelletier
@ca
Johanne Martel-Pelletier
@de
Johanne Martel-Pelletier
@en
Johanne Martel-Pelletier
@es
Johanne Martel-Pelletier
@fr
Johanne Martel-Pelletier
@ga
Johanne Martel-Pelletier
@nl
Johanne Martel-Pelletier
@sl
Johanne Martel-Pelletier
@sq
altLabel
Martel-Pelletier
@de
جوان مارتل بليتير
@ar
prefLabel
Johanne Martel-Pelletier
@ast
Johanne Martel-Pelletier
@ca
Johanne Martel-Pelletier
@de
Johanne Martel-Pelletier
@en
Johanne Martel-Pelletier
@es
Johanne Martel-Pelletier
@fr
Johanne Martel-Pelletier
@ga
Johanne Martel-Pelletier
@nl
Johanne Martel-Pelletier
@sl
Johanne Martel-Pelletier
@sq
P214
P101
P21
P214
P27
P31
P569
1952-04-20T00:00:00Z
P735
P7859
viaf-92500321